Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Mar 6, 2019: TACTI-mel data presented at World Immunotherapy Congress
Press releases — page 6
TACTI-mel data presented at World Immunotherapy Congress
March 5, 2019
Half Year Accounts
February 27, 2019
Immutep enters into collaboration with CYTLIMIC
January 6, 2019
Cleansing prospectus for issue of warrants
December 19, 2018
European patent granted for IMP321 & antibody combinations
November 28, 2018
Immutep granted European patent for IMP321
November 27, 2018
Positive interim TACTI-mel data presented at SITC
November 11, 2018
Immutep enters into collaboration with Pfizer & Merck KGaA
September 23, 2018
Progress towards clinical development of IMP761
September 2, 2018
Appendix 4E & 2018 Full Year Statutory Accounts
August 21, 2018
TACTI-mel Patient Recruitment Complete & Operational Update
August 6, 2018
Immutep receives IND approval from US FDA for IMP321
July 31, 2018
Immutep submits IND application with FDA
July 2, 2018
Mid-point of patient enrolment reached in AIPAC trial
June 18, 2018
Webcast slides for TACTI-mel clinical trial data
May 29, 2018
Response to ASX Price Query
May 15, 2018
Immutep raises A$6.85M through institutional placement
March 11, 2018
US patent grant for IMP701 antibody
March 5, 2018
Immutep receives A$686,704 R&D Tax Incentive
March 4, 2018
Outcome of DSMB Safety Review & Extension of TACTI-mel
February 8, 2018
Immutep receives USD1M milestone payment from EOC
February 1, 2018
European patent grant for IMP321 in cancer
November 21, 2017
Japanese Patent Grant for IMP731 Antibody
September 8, 2017
Japanese Patent Grants For IMP321 In Infectious Disease
September 5, 2017
PRR & Monash Uni receive funding grant for LAG-3 Research
August 30, 2017
Appendix 4E & 2017 Full Year Statutory Accounts
August 28, 2017
French government research cash rebate of A$1.3M received
August 16, 2017
Financial Update
July 17, 2017
2nd milestone payment to be received from Novartis
July 16, 2017
Approvals received to initiate INSIGHT clinical trial
July 10, 2017
Disclosure Under LR 3.10.5A and 7.1A.4(b)
July 5, 2017
Form 6-K
June 30, 2017
USD 5 Million Capital Raising
June 29, 2017
IMP321 demonstrates positive safety & efficacy qualities
June 4, 2017
Approval received to commence 3rd cohort of melanoma trial
April 19, 2017
$492k R&D Tax Incentive Refund Received
April 12, 2017
PRR completes recruitment for 2nd patient cohort
March 14, 2017
US patent granted for IMP321
March 1, 2017
French Research Tax Credit Payment Received
February 13, 2017
PRR commences randomised phase IIb clinical trial
January 19, 2017
Prima commences recruitment for 2nd cohort of melanoma trial
January 11, 2017
Prima Enters New MTA with CYTLIMIC
January 5, 2017
Prima announces new LAG-3 agonist antibody product candidate
January 2, 2017
Prima announces TACTI-mel clinical trial data
December 29, 2016
Prima announces AIPAC clinical trial data
December 21, 2016
Prima receives UK approval for AIPAC study
December 19, 2016
Wuxi & Prima sign MOU for strategic partnership
November 22, 2016
S&P DJ Indices Announces March Quarterly Review
November 7, 2016
S&P DJ Indices Announces March Quarterly Rebalance
November 6, 2016
Appendix 4E & 2016 Full Year Statutory Accounts
August 31, 2016